Diabetes in Control: Effectiveness of A GLP-1 Receptor Agonist Plus A TZD for Type 2 Diabetes

The study was done to examine the efficacy and safety of combination therapy with the GLP-1 receptor agonist exenatide plus the TZD pioglitazone versus basal-bolus insulin in poorly controlled type 2 diabetic patients with very high HbA1c (HbA1c>10%) on metformin plus sulfonylurea and long duration of disease.

Read the full story at Diabetes in Control

Share This Article!